tazarotene Topical Foam

Brand(s)
Fabior
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Stiefel Laboratories Inc (2014-01-08)
Oldest Current Product
2013-09-04
License(s)
NDA
RxNORM
TOPICAL FOAM\TAZAROTENE
FDAOB
TOPICAL\AEROSOL, FOAM\TAZAROTENE
SPL Active
TOPICAL\AEROSOL, FOAM\TAZAROTENE
SPL Moiety
TOPICAL\AEROSOL, FOAM\TAZAROTENE

product(s) by strength(s)

tazarotene 1 mg/ml topical foam

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1001450020FabiorNDAStiefel Laboratories Inc2013-09-04TAZAROTENETOPICALAEROSOL, FOAMNDA202428596fd7d0-6ae2-4736-990d-4d4f01f96965

application(s)

#idtitleapplicantapprovedpatentexclusivityapproved drug
1NDA202428FABIORSTIEFEL LABORATORIES INC2012-05-11p8808716, SUBSTANCENEW DOSAGE FORM [2015-05-11]NDA202428_001

application drug(s)

#idcategory/deprecatedingredient strength(s)routedose formrldapprovedapplication
1NDA202428_001RXTAZAROTENE (0.1%)TOPICALAEROSOL, FOAMTrue2012-05-11FABIOR

patent(s)

#idexpiration dateapplication(s)
1p8808716 (view patent)2030-02-24NDA202428

spl(s)

#idtitlecategorytypelabelerlast updateversionproduct(s)
1596fd7d0-6ae2-4736-990d-4d4f01f96965 (view SPL)These highlights do not include all the information needed to use FABIOR Foam safely and effectively. See full prescribing information for FABIOR Foam. FABIOR (tazarotene) Foam, 0.1%, for topical use Initial U.S. Approval: 1997prescriptionHuman PrescriptionStiefel Laboratories Inc2014-01-086001450020

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII